| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Acumen Pharmaceuticals, Inc. (ABOS) has 15 insiders with recent SEC Form 4 filings, including 9 buys and 0 sells. ABOS is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 893.3K | $2.22M | - | |
| CFO | 309.1K | $769.6K | - | |
| Other | 258.6K | $643.9K | - | |
| Pres | 220.9K | $550.0K | - | |
| COO | 126.9K | $316.0K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jul 21, 2023 | Ra Capital Management, L.P.52 | Director, 10% Owner | Buy | 5,161,290 | $7.75 | $39,999,997.50 | +65.5% | -52.8% | -61.2% | |
| Jul 6, 2021 | Stalfort John A III | Director | Buy | 35,000 | $16.00 | $560,000.00 | +25.5% | -25.0% | -72.8% | |
| Jul 6, 2021 | Hardie Robert D. | 10% Owner | Buy | 750,000 | $16.00 | $12,000,000.00 | +23.4% | -25.0% | -72.8% | |
| Jul 6, 2021 | Hardie Robert D. | 10% Owner | Buy | 312,500 | $16.00 | $5,000,000.00 | +10.3% | -25.0% | -72.8% | |
| Jul 6, 2021 | Manning Paul B53 | 10% Owner | Buy | 312,500 | $16.00 | $5,000,000.00 | +10.3% | -25.0% | -72.8% | |
| Jul 6, 2021 | Fountain Nathan B | Director | Buy | 6,250 | $16.00 | $100,000.00 | New | -25.0% | -72.8% | |
| Jul 6, 2021 | Sands Capital Ventures Discovery Fund Iii, L.P. | 10% Owner | Buy | 450,000 | $14.88 | $6,696,000.00 | +15.2% | -25.0% | -72.8% | |
| Jul 6, 2021 | Ra Capital Management, L.P.52 | Director, 10% Owner | Buy | 1,875,000 | $16.00 | $30,000,000.00 | +25.7% | -25.0% | -72.8% |